Bionano Genomics Inc. Watch

from 8-K 40 pages Securities Purchase Agreement

from 10-Q 14 pages Certain Information Contained in This Exhibit, Marked by […***…], Has Been Excluded From This Exhibit Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Option and Sublicense Agreement

from 10-Q 14 pages License Agreement This Agreement, Effective as of November 4, 2013 (The “Effective Date”), Is by and Between: New York University (Hereinafter “Nyu”), a Corporation Organized and Existing Under the Laws of the State of New York and Having a Place of Business at 70 Washington Square South, New York, New York 10012 and Bionano Genomics, Inc. (Hereinafter “Corporation”), a Corporation Organized and Existing Under the Laws of the State of Delaware and Having Its Principal Office at 9640 Towne Centre Drive, Suite 100, San Diego, Ca 92121. Recitals

from 10-Q 5 pages Amendment to the Non-Exclusive Patent License Agreement Dated 01 May 2014 (The “Amendment”) Effective as of 01 January 2018 (The “Effective Date”) Between Q Biotechnology C.V., a Dutch Company With a Place of Business at Hulsterweg 82 , 5912 Pl, Venlo, the Netherlands - The “Licensor” and Bionano Genomics, Inc, a Delaware (USA) Corporation With a Place of Business at 9640 Town Centre Drive, Suite 100, San Diego, Ca 92121, USA, - The “Licenssee” — - The Licensee and the Licensor Also Referred to Individually as “Party” and Together as the “Parties” -. Preamble 1. on 01 May 2014 the Parties Entered Into a Non-Exclusive Patent License Agreement (The “Agreement”). 2. Effective as of the Effective Date, the Parties Wish to Amend the Agreement With Regard to the Conversion to an Exclusive License in the Field A. Now Therefore, the Parties Agree the Following: 1. Amendment of the Agreement 1.1 Section 1, Subsection “Field” to the Agreement Shall Be Deleted and Replaced in Its Entirety as Follows

from 10-Q 11 pages Certain Information Contained in This Exhibit, Marked by […***…], Has Been Excluded From This Exhibit Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Non-Exclusive Patent License Agreement

from 10-Q 1 page Fourth Amendment to License Agreement

from 10-Q 2 pages Second Amendment to License Agreement

from 10-Q ~1 page First Amendment to License Agreement

from 10-Q 19 pages License Agreement Between Princeton University and Bionanomatrix LLC

from 10-Q 17 pages Certain Information Contained in This Exhibit, Marked by […***…], Has Been Excluded From This Exhibit Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. This Agreement Is Entered Into by Paramit Corporation, a California Corporation (Referred to in This Agreement as “Paramit”), and the Following Party: Bionano Genomics (Referred to in This Agreement as “Customer”). Customer Represents That It Is A: ☒ Corporation ☐ Limited Liability Company ☐ Other: Formed Under the Laws Of: ☐ California ☒ Delaware ☐ Other: 1. Recitals and Definitions

from 10-Q 109 pages Master Services Agreement

from 8-K 48 pages Securities Purchase Agreement

from 8-K 4 pages May 23, 2024 Bionano Genomics, Inc. 9540 Towne Centre Drive, Suite 100 San Diego, Ca 92121 Attn: R. Erik Holmlin Re: Agreement to Redeem Senior Secured Convertible Notes Due 2025 to the Addressees Set Forth Above

from 8-K 26 pages Registration Rights Agreement

from 8-K 8 pages Placement Agency Agreement

from 8-K 15 pages Subsidiary Guarantee

from 8-K 30 pages Security Agreement

from 8-K 43 pages Securities Purchase Agreement

from 8-K 40 pages Securities Purchase Agreement

from 8-K 4 pages Amendment to Initial Registered Note